In this webinar, Dr. Philip Thompson covers the mechanisms of action of current CLL therapies, methods for assessing resistance, treatment intolerance, and strategies for managing resistance. He discusses resistance to BTK and BCL2 inhibitors and explores new treatment strategies, including novel targeted therapies, antibody therapies, and CAR-T therapies for refractory CLL.